ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
April 19, 2018

Holding in company

Read More
April 18, 2018

Holding in company

Read More
April 17, 2018

Top line results of Lupuzor™ Pivotal Phase III Trial

Read More
March 28, 2018

Appointment of Joint Broker

Read More
March 23, 2018

Lupuzor™ ‘database lock’ confirmed for 6 April 2018

Read More
February 15, 2018

London Investor Evening – Monday 26 February 2018 @ 6pm

Read More
February 08, 2018

Holding in Company

Read More
February 05, 2018

Notification of Major Interest – Lanstead Increases Holding to over 5%

Read More
January 24, 2018

Successful Placing to Raise £10 Million

Read More
January 18, 2018

Completion of Lupuzor™ Pivotal Phase III Study and Initiation of Follow Up Study

Read More
  • 1
  • 2
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved